These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30378502)

  • 1. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 entry inhibitors: recent development and clinical use.
    Henrich TJ; Kuritzkes DR
    Curr Opin Virol; 2013 Feb; 3(1):51-7. PubMed ID: 23290628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
    Chahine EB
    Am J Health Syst Pharm; 2021 Feb; 78(5):376-388. PubMed ID: 33547469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 17. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.
    Fessel WJ; Anderson B; Follansbee SE; Winters MA; Lewis ST; Weinheimer SP; Petropoulos CJ; Shafer RW
    Antiviral Res; 2011 Dec; 92(3):484-7. PubMed ID: 22001594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
    Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.